National Toxicology Program

National Toxicology Program
https://ntp.niehs.nih.gov/go/10971

Target Organs and Levels of Evidence for TR-400

Toxicology and Carcinogenesis Studies of 2,3-Dibromo-1-Propanol (CASRN 96-13-9) in F344/N Rats and B6C3F1 Mice (Dermal Studies)

Chemical (Study Title)
CASRN
Peer Review DatePrimary UsesRoute/Exposure LevelsStudy Laboratory
2,3-Dibromo-1-propanol
96-13-9
06/23/1992Chemical intermediate for flame retardants, insecticides and pharmaceuticals. Topical Application
R: 0,188,375, M: 0,88,177 MG/KG/50 PER GROUP
Papanicolaou Research Institute

Levels of Evidence

Male Rats: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Nasal Cavity: ADENOMA 0/50 48/50 48/50
  • Mesothelium (Abdominal Cavity/Tunica Vaginalis): 0/50 1/50 4/50
  • Vascular System (Spleen): HEMANGIOMA 0/50 0/50 3/50 OR HEMANGIOSARCOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 4/50
  • Skin: SQUAMOUS CELL PAPILLOMA 1/50 3/50 0/50 OR SQUAMOUS CELL CARCINOMA 0/50 5/50 8/50 COMBINED 1/50 8/50 8/50; BASAL CELL NEOPLASMS, SEBACEOUS GLAND ADENOMA, OR KERATOACANTHOMA 0/50 20/50 31/50
  • Oral Cavity: SQUAMOUS CELL PAPILLOMA 0/50 40/50 33/50 OR SQUAMOUS CELL CARCINOMA 0/50 16/50 25/50 COMBINED 0/50 47/50 48/50
  • Esophagus: SQUAMOUS CELL PAPILLOMA 0/50 19/50 33/50
  • Forestomach: SQUAMOUS CELL PAPILLOMA 0/50 1/50 17/50
  • Intestines: ADENOCARCINOMA 0/50 8/50 11/50; ADENOMATOUS POLYP 1/50 13/50 29/50
  • Liver: NEOPLASTIC NODULES 0/49 3/50 2/50 OR CARCINOMA 0/49 1/50 3/50 COMBINED 0/49 4/50 5/50
  • Kidney Tubular Cell: ADENOMA 0/50 0/50 4/50
  • Zymbal Gland: ADENOMA 0/50 1/50 7/50 OR ADENOCARCINOMA 0/50 8/50 29/50 COMBINED 0/50 9/50 35/50
Non-Neoplastic Lesions
  • SKIN: HYPERKERATOSIS
  • NASAL CAVITY: EPITHELIAL DYSPLASIA
  • ESOPHAGUS: HYPERKERATOSIS
  • FORESTOMACH: HYPERKERATOSIS; ULCER; ACANTHOSIS
  • LIVER: PLEOMORPHISM; BASOPHILIC CHANGE; CLEAR CELL CHANGE; ANGIECTASIS
  • KIDNEY: NUCLEAR ENLARGEMENT; HYPERPLASIA
Female Rats: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Skin: SQUAMOUS CELL PAPILLOMA 0/50 0/50 2/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 3/50; BASAL CELL NEOPLASMS, SEBACEOUS GLAND ADENOMA OR KERATOACANTHOMA 0/50 3/50 18/50
  • Zymbal Gland: ADENOMA 0/50 7/50 3/50 OR ADENOCARCINOMA 1/50 2/50 19/50 COMBINED 1/50 9/50 22/50
  • Clitoral Gland: ADENOMA 0/50 1/50 3/50 OR ADENOCARCINOMA 0/50 0/50 3/50 COMBINED 0/50 1/50 6/50
  • Mammary Gland: ADENOCARCINOMA 0/50 0/50 5/50
  • Nasal Cavity: ADENOMA 0/50 44/50 49/50
  • Oral Cavity: SQUAMOUS CELL PAPILLOMA 0/50 27/50 41/50 OR SQUAMOUS CELL CARCINOMA 0/50 15/50 27/50 COMBINED 0/50 39/50 49/50
  • Esophagus: SQUAMOUS CELL PAPILLOMA 0/50 9/50 38/50
  • Forestomach: SQUAMOUS CELL PAPILLOMA 1/50 3/50 23/50
  • Intestines: ADENOCARCINOMA 0/50 3/50 4/49; ADENOMATOUS POLYP 0/50 12/50 37/50
  • Liver: NEOPLASTIC NODULES 0/50 10/50 11/50 OR CARCINOMA 0/50 2/50 6/50 COMBINED 0/50 11/50 14/50
  • Kidney Tubular Cell: ADENOMA 0/50 1/50 4/50
Non-Neoplastic Lesions
  • SKIN: HYPERKERATOSIS
  • NASAL CAVITY: EPITHELIAL DYSPLASIA
  • ESOPHAGUS: HYPERKERATOSIS
  • FORESTOMACH: HYPERKERATOSIS; EPITHELIAL DYSPLASIA
  • LIVER: PLEOMORPHISM; BASOPHILIC CHANGE; CLEAR CELL CHANGE; BILE DUCT HYPERPLASIA
  • KIDNEY: NUCLEAR ENLARGEMENT
Male Mice: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Skin: SQUAMOUS CELL PAPILLOMA 0/50 3/50 9/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 2/50 COMBINED 0/50 3/50 11/50; SEBACEOUS GLAND ADENOMA 0/50 1/50 8/50
  • Forestomach: SQUAMOUS CELL PAPILLOMA 0/50 12/50 20/50 OR SQUAMOUS CELL CARCINOMA 0/50 2/50 1/49 COMBINED 0/50 14/50 21/49
  • Liver: ADENOMA 1/50 2/50 9/50 OR CARCINOMA 0/50 0/50 3/50 COMBINED 1/50 2/50 11/50
  • Lung: ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 1/50 6/50
Non-Neoplastic Lesions
  • SKIN: HYPERPLASIA
  • FORESTOMACH: EPITHELIAL DYSPLASIA
  • LUNG: BRONCHIAL EPITHELIAL PLEOMORPHISM; FOCAL HYPERPLASIA
  • LIVER: EOSINOPHILIC CYTOPLASMIC CHANGE
Female Mice: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Skin: SQUAMOUS CELL PAPILLOMA 0/50 1/50 5/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 1/50 6/50; SEBACEOUS GLAND ADENOMA 0/50 3/50 2/50
  • Forestomach: SQUAMOUS CELL PAPILLOMA 0/50 12/49 17/50 OR SQUAMOUS CELL CARCINOMA 0/50 7/47 6/50 COMBINED 0/50 18/49 19/50
May Have Been Related
  • Lung: ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 3/50 4/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 0/50 0/50 COMBINED 1/50 3/50 4/50
Non-Neoplastic Lesions
  • SKIN: HYPERPLASIA
  • FORESTOMACH: EPITHELIAL DYSPLASIA
  • LUNG: BRONCHIAL PLEOMORPHISM; FOCAL HYPERPLASIA


NTP is located at the National Institute of Environmental Health Sciences, part of the National Institutes of Health.